http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sanchit Sharma ),( Arti Gupta ),( Saurabh Kedia ),( Samagra Agarwal ),( Namrata Singh ),( Sandeep Goyal ),( Saransh Jain ),( Vipin Gupta ),( Pabitra Sahu ),( Sudheer Kumar Vuyyuru ),( Bhaskar Kante 대한장연구학회 2021 Intestinal Research Vol.19 No.3
Background/Aims: Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India. Methods: This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI >70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response. Results: Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2-6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260-320] vs. 240 [180-280], P=0.001) and 8 weeks (baseline 290 [260-320] vs. 186 [160-240], P=0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n=4), B2 (n=18), and B3 (n=9) phenotypes were 50%, 78.8%, and 100% respectively (log-rank test, P=0.093). The response rates at 8 weeks with polymeric (n=8) and semi-elemental diet (n=23) were 75% and 82.6% respectively (log-rank test, P=0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002-1.017; P=0.046) predicted response to EEN. Conclusions: EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN. (Intest Res 2021;19:291-300)
Energy Efficient Traffic Light Controller Design on 28nm FGPA
Arpit Gupta,Aarushi Sapra,Alisha Nagpal,Sanchit Sharma 보안공학연구지원센터 2015 International Journal of Smart Home Vol.9 No.10
In this work, our focus is on study and analysis of power and junction temperature at different temperatures and at different capacitance values. Kintex7 is 28-nm FPGA on which we implement our circuit to re-assure power reduction and reduction in junction temperature in sequential circuit. Varying the values of capacitance and temperature enhance the efficiency of the Energy Efficient Traffic Light Controller design. This paper basically deals with FSM (Finite State Machine) and is implemented on FPGA. FGPA is preferred because of its high speed and is inexpensive. Traffic lights are beneficial in managing the traffic, reducing accidents rate, relaxing traffic cop’s job, minimizing fuel consumption and emission and save time. The performance of our energy efficient traffic lights is evaluated and tested through simulations on Xilinx software development kit. For 2.4GHz operating frequency, there is 47.71% reduction in total power dissipation, 69.94% reduction in IOs power dissipation, and 0.78% reduction in junction temperature when we use 28nm FPGA and temperature is 25 degree Celsius and capacitance is scaled down from 100pF to 20pF. For 10GHz operating frequency, there is 54.81% reduction in total power dissipation, 70.11% reduction in IOs power dissipation, 3.52% reduction in leakage power dissipation and 1.92% reduction in junction temperature when we use 28nm FPGA and temperature is 50 degree Celsius and capacitance is scaled down from 100pF to 20pF.
Yu Jun Wong,Chen Zhaojin,Guilia Tosetti,Elisabetta Degasperi,Sanchit Sharma,Samagra Agarwal,Liu Chuan,Chan Yiong Huak,Li Jia,Qi Xiaolong,Anoop Saraya,Massimo Primignani 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.1
Background/Aims: The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients. Methods: cACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of “treating definite CSPH” strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis. Results: One thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0–7.4). “Probable CSPH” is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that “treating definite CSPH” strategy is superior to “treating all varices” or “treating probable CSPH” strategy to prevent decompensation using NSBB. Conclusions: Non-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.